BRD4 and Hepatic fibrosis: Furthermore, we recently uncovered that anti-fibrotic effect of miR-29a is associated with inhibition of bromodomain-containing protein 4 (BRD4) in HSC [38], which represents a novel therapeutic target of liver fibrosis [157].